SCHEMBL7250017

SCHEMBL7250017

Cn1cc2c(n1)-c1c(N(C(=O)OCc3ccccc3)c3ccccc3)sc(C(N)=O)c1CC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.36
CCNC P24863 11/20 0.35
CDK8 P49336 11/20 0.35
CDK19 Q9BWU1 11/20 0.35
IKBKB O14920 1/20 0.34
CCNA2 P20248 2/20 0.33
CDK2 P24941 2/20 0.33
CCNA1 P78396 2/20 0.33
AURKA O14965 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
BTK Q06187 1/20 0.32
CDK9 P50750 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
DRD2 P14416 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7247769 0.93 DRD4 (0.38) DRD4CCNCCDK8CDK19SMN1; SMN2
SCHEMBL7241267 0.90 ADORA2A (0.39) DRD4CCNA2CDK2CCNA1SMN1; SMN2
SCHEMBL7248713 0.83 CCNC (0.53) DRD4CCNCCDK8CDK19CCNA2
SCHEMBL7248643 0.77 DRD4 (0.44) DRD4CCNCCDK8CDK19IKBKB
SCHEMBL7249485 0.76 CCNC (0.50) CCNCCDK8CDK19CDK9
SCHEMBL7243383 0.73 CCNC (0.41) DRD4CCNCCDK8CDK19CCNA2
SCHEMBL7249475 0.72 CCNC (0.41) DRD4CCNCCDK8CDK19AURKA
SCHEMBL7246693 0.71 DRD4 (0.67) DRD4CCNCCDK8CDK19CDK9
SCHEMBL7241345 0.71 CCNC (0.50) DRD4CCNCCDK8CDK19CCNA2
SCHEMBL7242282 0.71 CCNC (0.40) DRD4CCNCCDK8CDK19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030158245-A1 Fused heterocyclic derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158245-A1 Fused heterocyclic derivatives, their production and use TST, STS, AHR DRD4 567/4885CCNC 2012/4885CDK8 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.